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Abstract: Cholangiocarcinoma (CCA) is a very heterogeneous cancer in many aspects including epidemiology, risk 
factors, clinical presentation and genetics. Medical literature reflects this feature especially in terms of differences of 
clinical presentation among the intrahepatic/extrahepatic subtypes and according to related risk factors and geographic 
areas. Consequently these tumors are often challenging to diagnose and treat and the prognosis is poor. 
This manuscript deals with the clinical presentation and epidemiology of cholangiocarcinoma. 
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INTRODUCTION 
Cholangiocarcinoma (CCA) is a relatively rare tumor 
that develops along the biliary tract. It is the most 
common biliary tract malignancy, accounting for 
approximately 3% of all gastrointestinal tumors with an 
incidence of about 3/100000 [1]. Anatomically CCA is 
commonly classified in intrahepatic CCA (I-CCA) and 
extrahepatic CCA (E-CCA) in keeping with anatomical 
position in relation to the second-order bile ducts. The 
latter is distinguished in perihilar-CCA (or Klatskin 
tumor) and distal extrahepatic-CCA. The extrahepatic 
subtype is more common than I-CCA although the 
incidence of I-CCA is increasing [2]. Conversely the 
incidence of E-CCA is substantially stable or slightly 
decreased [3, 4]. The intrahepatic-CCA, the perihilar-
CCA and distal extrahepatic-CCA respectively account 
for 6-8%, 50-67% and 27-42% of all cholangiocar- 
cinomas (Figure 1) [5, 6]. The main risk factors are 
linked to geographic area and this condition leads to 
significant differences in the incidence rates (e.g. the 
incidence of I-CCA is 85/100000 in northeast Thailand 
and 3.36/100000 in Italy) [7]. These tumors are often 
challenging to diagnose and treat. The diagnosis 
results from an integration of clinical information, 
biochemical parameters, tumor markers, imaging 
studies, cytology and/or histology. Most of the E-CCAs 
occurs with the appearance of jaundice or related 
cholangitis at onset and, unlike the I-CCAs, only in a 
few cases patients are completely asymptomatic at 
diagnosis. Conversely a large percentage of patients  
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with I-CCA are asymptomatic at diagnoses and clinical-
radiological findings are usually related with 
macroscopic features.  
 
Figure 1: Percentage of intrahepatic-CCAs (I-CCAs), 
perihilar-CCAs and distal extrahepatic-CCAs (E-CCAs) within 
all cholangiocarcinomas [5, 6]. 
Unfortunately the majority of patients present with 
advanced disease. Complete surgical resection is the 
only potentially curative treatment but it is feasible only 
in a small percentage of cases [8]. At present, unlike 
other gastrointestinal cancers, such as rectal cancer, 
there are not definitive data about neoadjuvant therapy 
for CCA [9]. A trial from the Mayo Clinic showed 
positive results with a combined neoadjuvant therapy 
(5-FU-based chemo-radiation, brachitherapy and oral 
capecitabine) followed by liver transplantation in highly 
selected patients with perihilar-CCA [10, 11]. In 
presence of high-risk features (lymphonodal 
metastases, lymphovascular invasion, satellitosis) an 
adjuvant therapy should be considered, even if there 
aren't definitive recommendations [12, 13]. 
Chemotherapy (cisplatin plus gemcitabine) represents 
the standard-of-care for metastatic patients [14, 15]. 
Loco-regional therapies may be proposed for locally 
advanced or oligometastatic disease in selected cases. 
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Endoscopic (or percutaneous) biliary drainage is useful 
in case of jaundice to prevent liver failure and 
cholangitis [16]. All in all, the prognosis is poor. This 
paper aims to be a quick guide on the clinical features 
of CCA with a brief analysis of the most important risk 
factors related to this disease. 
RISK FACTORS  
In more than 60% of CCA cases there are no 
detectable putative risk factors [17]. The presence of 
persistent inflammation is the common condition of the 
main known risk factors associated with the 
development of cholangiocarcinoma. Consequently this 
neoplasm could be considered a prototype of 
inflammation-associated cancer. Persisted tissue 
damage induces the proliferation of stem cells as a first 
step in the cancer process [7, 17]. Metaplasia usually 
occurs in a context of chronic inflammation and injury. 
The recent finding of stem cell niches in peribiliary 
glands of extrahepatic/intrahepatic biliary tree is 
interesting because these cells may play a primary role 
in the origin of CCA [18, 19]. 
According to the above, chronic diseases primarily 
affecting the extrahepatic bile ducts and/or large 
intrahepatic bile ducts such as primary sclerosing 
cholangitis (PSC), Caroli's disease, Vater ampulla 
adenoma, bile duct adenoma, bile duct cysts, 
hepatolithiasis and choledocholithiasis are related to 
both the E-CCA and I-CCA development [20]. 
Cholelithiasis and probably cholecystectomy, bilio-
enteric surgical drainage and pancreatico-biliary 
maljunction, are involved in the development of E-CCA 
in relation to the presence of bile duct dilatation and 
stagnation of bile [7]. 
PSC is one of the best-known risk factors for E-
CCAs in the Western world. Among patients with PSC, 
the prevalence of CCA ranges from 5% to 10%, with an 
overall risk of 0.5% to 1.5%/year. The neoplasm occurs 
most often as a desmoplastic ductal lesion but may 
sometimes present itself as a focal I-CCA. The tumor is 
often detected within the first three years after the initial 
diagnosis of PSC. In the 20-30% of cases the 
diagnosis is synchronous, within one year in the 50% of 
cases [21]. 
Some factors (i.e. alcohol use, smoking, obesity, 
diabetes, longer duration of the concomitant 
inflammatory bowel disease, colorectal cancer or 
dysplasia in patients with ulcerative colitis, biliary 
stones, polymorphism in the NKG2D gene, exposure to 
asbestos) could modify CCA risk even if they are still 
debated (Table 1) [2, 22]. Concerning I-CCA, viral and 
metabolic cirrhosis (induced by chronic hepatitis virus 
C and virus B infection or by hemochromatosis, 
Wilson’s disease and non-alcoholic steato-hepatitis) 
can be considered as recently emerging risk factor with 
different strong of evidence [23-25]. 
Table 1: Risk Factors for Intra and Extrahepatic 
Cholangiocarcinoma 
Established Risk Factors (Strong Evidence) 
primary sclerosing cholangitis (PSC), Caroli's disease, hepato-
choledocholithiasis, Vater ampulla adenoma, bile duct adenoma, 
bile duct cysts, HCV cirrhosis, fluke infections (O. viverrini, 
Clonorchis sinensis, Schistosomiasis japonica), bacterial infection 
(Salmonella typhi), thorotrast. 
Still Debated Risk Factors (Moderate or Weak Evidence) 
cholecystectomy, bilio-enteric surgical drainage, 
pancreaticobiliary maljunction, alcohol use, obesity, diabetes, 
smoking, hemochromatosis, Wilson’s disease, non alcoholic 
steato-hepatitis, HBV cirrhosis, longer duration of the concomitant 
inflammatory bowel disease, biliary stones, polymorphism in the 
NKG2D gene, exposure to asbestos, exposure to other xenobiotic 
Abbreviations: HBV (hepatitis B virus); HCV (hepatitis C virus); PSC 
(primary sclerosing cholangitis). 
In Asian countries additional relevant risk factors 
are Opisthorchis viverrini and Clonorchis sinensis 
(flukes that colonize the hepatobiliary ducts), but also 
Schistosomiasis japonica and Salmonella typhi in 
endemic regions [20]. Fluke infection induces a chronic 
inflammation resulting in increased cell turnover and 
susceptibility to endogenous and exogenous 
carcinogens infection [26]. Finally there are important 
evidences of association between the exposure to 
thorotrast (an old, no longer employed, radio-contrast 
agent) and hepatic malignancy, including CCA; while 
the role of other xenobiotic (i.e. nitrosamine, dioxins, 
vinyl chlorides) is still under investigation [27-29]. 
CLINICAL FEATURES 
The clinical presentation is different from I-CCA and 
E-CCA. Moreover, clinical symptoms are usually late 
and do not facilitate an early diagnosis. Patients with 
extra-hepatic neoplasms usually present obstructive 
jaundice and sometimes complications such as 
cholangitis. Conversely patients with I-CCAs may 
present more non-specific symptoms like abdominal 
pain, malaise, night sweats, weight loss and loss of 
appetite [5]. 
The onset of disease was estimated to occur in a 
very wide range of ages. The median age at 
presentation ranged from 59 to 71 years. Alvaro et al 
reported that the age at diagnosis was significantly 
higher for E-CCA than I-CCA [30]. As regards I-CCAs, 
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a slight prevalence of male was observed in series 
analysed from Italy, United States, France and Greece 
[30-33]. E-CCAs were similarly distributed by sex [30]. 
Patients with an early stage I-CCA disease are 
usually asymptomatic [34]. Jaundice or cholangitis do 
not manifest until hilar infiltration [15, 35]. 
Hepatomegaly, night sweats and ascites usually 
appear late. Often disease remains silent even in 
advanced stage. An incidental diagnosis occurs in 12-
30% of cases. A 30-73% of patients are asymptomatic 
at diagnosis [30, 31, 36, 37]. The main clinical 
manifestations included upper abdominal discomfort, 
pain or sense of fullness (42-65%), asthenia (8%), 
abdominal distension (2-4%), jaundice (2,5-3%), 
nausea (3%), lower back pain (2.5%), abdominal mass, 
pruritus (4%) and weight loss (18%) (Table 2) [30, 37]. 
The analysis of the sub-setting of patients with 
abdominal pain demonstrated that this condition 
without other symptoms represents a frequent clinical 
presentation of I-CCA (19.8%) with respect to E-CCA 
(3.9%) [30]. Conversely abdominal pain with jaundice 
occurs 2-fold more frequently in E-CCA than I-CCA 
(24.5% vs. 10.3%). Pruritus was rarely encountered 
both in E-CCA (6.9%) and in I-CCA (4.3%) [30]. As 
results, an early diagnosis of I-CCA is very difficult to 
achieve due to a specific presentation, the lack of early 
symptoms or reliable tumor biomarkers and the wide 
range of differential diagnoses. 
Otherwise, clinical presentation and radiological 
findings of I-CCA correlate with the pattern of growth: 
mass-forming (mass lesion in the liver and spread 
based on the intrahepatic metastasis), intraductal 
papillary (papillary projection into the ductal lumen), 
periductal infiltrating (spreading along the bile duct) and 
mixed types (neoplasms with mixed features) [38-40]. 
Interestingly this morphologically based classification in 
three principal subtypes (plus mixed types) relates with 
growth characteristic and natural history of the tumor 
[41, 42]. The mass-forming type is the most commonly 
subtype of ICC. The intraductal growth type, which 
accounts for about a 4% of I-CCAs, seems to have a 
significantly better prognosis [43-45]. Other features for 
each subtype have been reported, sometimes with 
discordant results due to the limited number of cases 
from the single centers. 
As regards E-CCA, the neoplastic obstruction of the 
bile duct leads to the onset of jaundice, cholangitis and 
liver failure. Other symptoms of biliary obstruction such 
as pale stools, dark urine and pruritus are usually 
present. With some exceptions, despite the more early 
appearance of jaundice, even for the E-CCA the 
diagnosis is delayed. The problem of differential 
Table 2: Signs and Symptoms of Cholangiocarcinomas 
Subtype Very Early Early Late 
I-C
C
A
 
asymptomatic  
 
usually asymptomatic 
jaundice or cholangitis only if hilar 
infiltration   
 
upper abdominal discomfort 
pain or sense of fullness 
asthenia 
abdominal distension  
nausea, hyporexia 
weight loss  
lower back pain  
abdominal mass 
pruritus  
hepatomegaly 
night sweats  
ascites  
jaundice or cholangitis  
(if hilar infiltration)  
E-
C
C
A
 asymptomatic jaundice  
(if intra-ductal growth in the 
common bile duct or hilum) 
 
jaundice or cholangitis 
pancreatitis 
(if near Wirsung duct) 
 
jaundice 
cholangitis 
pancreatitis   
(if near Wirsung duct) 
night sweats 
nausea, hyporexia 
weight loss  
upper abdominal discomfort 
pain or sense of fullness 
ascites  
pruritus  
asthenia 
Signs and symptoms that may occur as a consequence of the evolution of the tumor. 
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diagnosis is relevant. Over 80% of proximal biliary 
obstructions are secondary to neoplastic conditions, 
while the remaining 15-20% is caused by benign 
strictures (such as sclerosing cholangitis, 
choledocholithiasis, Mirizzi’s syndrome and idiopathic 
benign stricture). In addition other malignancies 
secondarily involving the hepatic hilum may present 
with similar symptoms. There are no reported 
significant differences in most of the clinical variables 
between patients with E-CCA or patients with benign 
and other malignant obstructions, with the exception of 
fatigue [46]. 
Several elevated laboratory parameters may be 
suggestive although not diagnostic of CCA. The 
biochemical profile of patients with E-CCA is usually 
indicative of a status of biliary obstruction (increase in 
total and direct bilirubin, alkaline phosphatase and γ-
glutamyltransferase). Singal et al. reported a median 
bilirubin level of 9.4 mg/dL in patients with E-CCA 
compared with a median bilirubin level of 1.0 in those 
with I-CCA [33]. Plasma serum markers (CA19-9 and 
CEA) may be useful for differential diagnoses even if 
the diagnostic utility of CA 19-9 and CEA is limited due 
to their low sensitivity (50-63% and 15-20%, 
respectively) [47-50]. In the context of primary 
sclerosing cholangitis the estimated sensitivity and 
specificity of CA 19-9 in predicting CCA are 
respectively 38-89% and 50-98% [51]. In these 
conditions the measurement of serum carbohydrate 
antigen (CA 19-9) could be useful despite the moderate 
sensitivity [52]. A CA 19-9 cut off of 130 U/ml in the 
absence of bacterial cholangitis detects CCA with 79% 
sensitivity and 98% specificity [53]. Recently it was 
shown that patients with PSC and/or CCA have 
different miRNA profiles in bile and serum [54]. The 
combination of specific miRNAs seems further improve 
the specificity and accuracy of diagnosis, although 
these findings need to be validated in larger series [55]. 
Furthermore, concerning the biochemical profile, 
elevated CA 19-9 and hyperbilirubinaemia are correla- 
ted with poor survival rates [33, 56]. Significantly higher 
CA 19-9 levels are reported in patients with unresecta- 
ble CCA than patients with resectable CCA [57]. 
CONCLUSION 
As described above, the clinical presentation of 
cholangiocarcinoma depends greatly on the site where 
the cancer develops and on the “height” and the extent 
of the obstruction of the biliary tree.  
The classification of these neoplasms is 
substantially based on the macroscopic and 
microscopic histopathologic features. Further work is 
needed to define the molecular and genetic profile of 
different types of CCA. 
No reliable method of early detection is currently 
available. Sometimes an early diagnosis is possible in 
patients with E-CCA if there is a complete obstruction 
of bile flow from the initial development of the disease. 
Unfortunately, even in this circumstance, the 
therapeutic approach does not always allow high rates 
of healing due to the limits of surgery on such a 
complex anatomical district. The identification of novel 
serum markers could help in the near future to achieve 
more accurate and earlier diagnosis. This could lead to 
the advent of minimally invasive approaches to achieve 
radical treatment or to limit the rate of unresectable 
patients and non-radical resections. 
At the current state the diagnosis and treatment of 
cholangiocarcinoma, especially if surgery is not 
feasible, remain a tough challenge in the field of the 
gastro-intestinal oncology. 
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